P3 Health Partners Inc. filings document a public population health management company with Class A common stock and warrants referenced in Exchange Act reports. The company’s Forms 8-K report operating results, management services agreements under its Care Enablement Model, ACO management arrangements, amendments to unsecured promissory notes, and debt and preferred stock actions tied to capital structure and Nasdaq listing-compliance matters.
Proxy filings describe annual meeting procedures, stockholder voting mechanics and corporate governance matters. The filing record also covers material agreements involving subsidiaries, unregistered equity securities, charter and bylaw amendments, significant holder financing relationships, and disclosures connecting P3’s value-based care model to revenue, medical margin and operating performance.
P3 Health Partners Inc. reports actions taken to regain compliance with Nasdaq’s stockholders’ equity requirement under Listing Rule 5550(b)(1), which sets a minimum of $2.5 million in equity. The company undertook a major balance sheet recapitalization.
On April 27, 2026, about $252,479,967 of outstanding promissory notes, including principal, accrued interest and back-end fees, were exchanged into non-convertible, non-voting, non-listed preferred stock. In addition, affiliates of Chicago Pacific Founders agreed to purchase up to $70.0 million of units consisting of Series D 19.5% Cumulative Preferred Stock and warrants, of which $30.0 million of units had been sold.
The unaudited pro forma balance sheet shows long-term debt falling from $259,569 thousand to $63,907 thousand and total stockholders’ equity shifting from a deficit of $(143,548) thousand to positive equity of $82,114 thousand. The company believes it now satisfies Nasdaq’s stockholders’ equity requirement, though Nasdaq will continue to monitor ongoing compliance.
P3 Health Partners Inc. reported Q1 2026 operating revenue of $386.4M, up from $373.2M a year earlier, driven mainly by capitated Medicare Advantage contracts. Medical expense fell sharply, turning operating results from a loss to operating income of $8.2M.
The company posted net income of $3.0M versus a prior-year net loss of $44.2M, and Adjusted EBITDA improved to $25.8M from a loss of $22.2M. However, it still used $27.5M of cash in operating activities, had a working capital deficit of $353.3M, stockholders’ deficit of $143.5M, and long-term debt of $379.3M at double‑digit interest rates.
Management states that substantial doubt exists about the company’s ability to continue as a going concern without additional financing or other actions. After quarter‑end, P3 exchanged about $252.5M of related‑party promissory notes into new preferred stock and raised $30.0M of additional preferred capital with attached warrants, while up to $40.0M more preferred funding remains available under the purchase agreement.
P3 Health Partners reported a sharp improvement in results for the quarter ended March 31, 2026. Total revenue was $386.4 million, up 4% year over year, as per-member revenue rose 14% helped by contract restructuring, rate progression, and illness-burden performance.
The company generated medical margin of $73.7 million, or $231 per member per month, and turned to net income of $3.0 million from a $44.2 million loss a year earlier. Adjusted EBITDA reached $25.8 million, or $81 PMPM, versus a prior-year adjusted EBITDA loss.
At-risk membership was about 106,000 members, down 10% as the company intentionally rationalized its network and payers. Reflecting stronger performance, management raised full-year 2026 adjusted EBITDA guidance to a midpoint of $40 million, within a range of $20–$60 million, on projected revenue of $1.5–$1.65 billion.
P3 Health Partners Inc. is calling a fully virtual 2026 annual stockholder meeting on June 9, 2026. Holders of Class A and Class V common stock as of April 10, 2026, totaling 3,318,290 Class A shares and 3,919,124 Class V shares, may vote.
Stockholders will elect three Class II directors, ratify BDO USA, P.C. as auditor, cast an advisory say‑on‑pay vote, and decide whether to approve the potential issuance of up to 3,341,130 Class A shares upon exercise of warrants held by VBC Growth SPV 5, LLC.
The warrants were issued alongside a Promissory Note providing up to $70 million of funding to subsidiary P3 Health Group, LLC, bearing 19.5% annual interest and various upfront and back-end fees. The proxy also details board structure, committee work, executive pay, and 2025 audit fees of $2,003,400.
P3 Health Partners Inc. entered a major restructuring with its largest investor, Chicago Pacific Founders, to help regain compliance with Nasdaq’s stockholders’ equity requirement. About $252.48 million of promissory note debt will be exchanged into several series of non‑convertible, non‑voting cumulative preferred stock with a $100 stated value per share.
The company also agreed to sell up to $70 million of additional preferred-stock-and-warrant units, of which $10 million closed initially. The new preferred ranks senior to all common stock, carries dividend rates up to 19.5%, and is paired with long-dated warrants for Class A common shares.
P3 Health Partners Inc. is soliciting proxies for its virtual 2026 Annual Meeting on June 9, 2026
The proxy seeks stockholder votes on director elections, ratification of BDO as auditor, a non-binding say-on-pay, and Nasdaq approval under Rule 5635(d) to permit issuance of up to 3,341,130 Class A shares issuable upon exercise of warrants held by VBC Growth SPV 5, LLC. The materials disclose the May 2025 financing that includes a $70.0M promissory note with staged tranches, high interest (19.5% per annum), related warrants at varying exercise prices, and a subordination agreement. The Board recommends votes in favor of the proposals.
P3 Health Partners Inc. reports significant financial strain in its 2025 annual filing, with management concluding there is substantial doubt about the company’s ability to continue as a going concern. The company ended December 31, 2025 with $25.0 million in unrestricted cash, $336.7 million of debt (including $45.0 million current), and $287.8 million of unpaid claims, after recording a $323.1 million net loss and building an accumulated deficit of $651.1 million.
P3 operates a physician-led, value-based care platform focused on Medicare Advantage, with capitated contracts where four health plans generated about 75% of 2025 revenue. It manages an "Up‑C" structure and owned roughly 46% of P3 Health Group, LLC as of December 31, 2025.
The filing highlights heavy reliance on raising additional capital in 2026, tight debt covenants that required waivers, and regulatory pressure, including California DMHC finding Medcore HP below required tangible net equity and requiring a corrective action plan. P3 also cites risks around California solvency rules, Nasdaq listing compliance, history of losses, and dependence on a few major payors and physician partners.
P3 Health Partners Inc. reported full-year 2025 revenue of $1.46 billion, slightly below $1.50 billion in 2024, with at-risk membership down about 8% to roughly 116,000. The company posted a 2025 net loss of $323.1 million, compared with a $310.4 million loss the prior year.
Adjusted EBITDA loss improved modestly to $161.3 million from $167.2 million, and normalized Adjusted EBITDA loss narrowed to $149.1 million from $193.0 million. For 2026, P3 guides Adjusted EBITDA in a range of $(20) million to $40 million, with a midpoint of $10 million, implying roughly $170 million year-over-year improvement.
P3 Health Partners Inc. reported a new multi-year services arrangement with a large nonprofit health insurer in Nebraska. Through a Statement of Work under an existing Master Services Agreement, P3 will deliver clinical, operational and data-driven support to primary care providers in the insurer’s Medicare Advantage network.
The client will pay management services fees for performance years 2026 and 2027, with the financial structure shifting to a global risk agreement starting in 2028. The Master Services Agreement runs through December 31, 2030 and then renews annually unless either party gives 180 days’ notice.
Both parties have termination rights for material breach, insolvency or change of control, and the client may also terminate on 90 days’ notice if 2026 performance metrics are not met or certain key personnel depart. If the client does not pursue a Medicare Advantage bid for 2027–2028, the Statement of Work ends and the client owes a break-up fee tied to P3’s service and termination-related costs, subject to an agreed cap. P3 will also provide termination assistance services to help transition work back to the client or its designee.
P3 Health Partners Inc. disclosed that its subsidiary, P3 Health Group, LLC, amended an existing unsecured promissory note with VBC Growth SPV 5, LLC. The amendment extends the availability period for the note’s third funding tranche, keeping the remaining $19.0 million accessible for one or more draws through June 30, 2026. All other terms of the original note dated May 29, 2025 remain unchanged, so this update primarily affects timing of access to already agreed financing rather than the total borrowing capacity.